諾泰生物(688076.SH):2023年度淨利預增16.18%到23.93%
格隆匯12月27日丨諾泰生物(688076.SH)公佈2023年年度業績預吿,經財務部門初步測算,公司預計2023年年度實現營業收入人民幣90,000.00萬元到100,000.00萬元,與上年同期(法定披露數據)相比,將增加24,870.83萬元到34,870.83萬元,同比增加38.19%到53.54%。
預計2023年年度實現歸屬於母公司所有者的淨利潤為15,000.00萬元到16,000.00萬元,與上年同期(法定披露數據)相比,將增加2,089.34萬元到3,089.34萬元,同比增加16.18%到23.93%。
預計2023年年度實現歸屬於母公司所有者的扣除非經常性損益的淨利潤為15,000.00萬元到16,000萬元,與上年同期(法定披露數據)相比,將增加6,690.73萬元到7,690.73萬元,同比增加80.52%到92.56%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.